Holen Sie sich die Stockscreener-App
18.49
28.94%
4.15
Handel nachbörslich:
19.30
0.81
+4.38%
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations - MSN
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Clears Existing Data For Sonelokimab BLA In Hidradenitis Suppurativa - simplywall.st
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations - Stocktwits
MoonLake Options Trading: A Deep Dive into Market Sentiment - Benzinga
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation - FinancialContent
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug - Citeline News & Insights
MoonLake price target raised to $32 from $26 at H.C. Wainwright - TipRanks
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission (NASDAQ:MLTX) - Seeking Alpha
MLTX Analyst Rating: HC Wainwright & Co. Raises Price Target to $32.00 | MLTX Stock News - GuruFocus
BTIG Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
Moonlake Immunotherapeutics stock upgraded to Buy at BTIG on FDA feedback - Investing.com Nigeria
Will MoonLake's Clinical Milestones Send Investors Over The Moon? - RTTNews
Will MoonLake Immunotherapeutics stock benefit from AI adoptionJuly 2025 Update & High Conviction Trade Alerts - ulpravda.ru
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (MLTX) Is Up 20.0% After FDA Clears Existing SLK Data For HS BLA Path - Yahoo Finance
What margin trends mean for MoonLake Immunotherapeutics stockQuarterly Trade Review & High Conviction Investment Ideas - ulpravda.ru
Will MoonLake Immunotherapeutics stock reach all time highs in 2025CEO Change & Growth Focused Entry Reports - ulpravda.ru
Will MoonLake Immunotherapeutics stock benefit from sector rotationWeekly Gains Summary & Low Drawdown Momentum Trade Ideas - ulpravda.ru
MoonLake Immunotherapeutics Stock Collapses. Why It’s Down 88%. - MSN
Biopharma bites: A flurry of financings headlined by Diagonal, plus updates from Servier, MoonLake - FirstWord
MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials - TechStock²
Will MoonLake Immunotherapeutics stock rally after Fed decisionsMarket Sentiment Report & Consistent Profit Trading Strategies - ulpravda.ru
Why MoonLake Immunotherapeutics stock could rally in 20252025 Top Gainers & Safe Investment Capital Preservation Plans - ulpravda.ru
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating - TipRanks
Biotech Soars 27% On FDA Deal For Beleaguered Skin Drug - Investor's Business Daily
MoonLake soars 45% after FDA clears path for key skin drug | Tap to know more | Inshorts - Inshorts
MLTX Surge: Will The Momentum Last? - StocksToTrade
What is the fair value of MoonLake Immunotherapeutics stock nowMarket Growth Review & Technical Entry and Exit Tips - ulpravda.ru
MoonLake States FDA Might Permit Skin Medication Submission Without Additional Studies, Shares Surge - Bitget
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars - Benzinga
MoonLake revives FDA push; Biotech trio to debut in Hong Kong - Endpoints News
De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026 - TipRanks
Can MoonLake Immunotherapeutics stock hit record highs again2025 Earnings Impact & Risk Controlled Swing Trade Alerts - ulpravda.ru
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $34 - 富途牛牛
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street - Investing.com South Africa
MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating - TipRanks
MoonLake Immunotherapeutics Shares Rise on FDA Alignment to File Application Without New Trials - MarketScreener
MoonLake provides update following positive feedback from U.S. FDA for SLK - TipRanks
Clear Street Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $45 - 富途牛牛
MLTX Stocks: Is the Price Right? - timothysykes.com
Why Did MLTX Stock Jump 45% In Pre-Market Today? - Stocktwits
MoonLake Immunotherapeutics price target raised to $45 from $12 at Clear Street - TipRanks
MoonLake Advances Sonelokimab After Positive FDA Feedback - TipRanks
Moonlake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. Fda - MarketScreener
FDA confirms MoonLake’s path to HS drug approval without additional trials - Investing.com
FDA confirms MoonLake’s path to HS drug approval without additional trials By Investing.com - Investing.com South Africa
MoonLake lead drug needs no additional trials (MLTX:NASDAQ) - Seeking Alpha
MoonLake stock soars after FDA feedback on HS treatment path By Investing.com - Investing.com South Africa
MoonLake stock soars after FDA feedback on HS treatment path - Investing.com
MoonLake Immunotherapeutics Announces Positive FDA Feedback on SLK - TradingView — Track All Markets
MoonLake Immunotherapeutics Announces Positive Outcome from - GlobeNewswire
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG - TipRanks
Will MoonLake Immunotherapeutics stock gain from strong economy2026 world cup usa national team quarterfinals playmakers low block defense odds analysis preview - ulpravda.ru
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3%Time to Sell? - MarketBeat
(MLTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a 6.66% Potential Upside in Biotechnology - DirectorsTalk Interviews
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):